Article
Implications of heterogeneity in multiple myeloma.
BioMed research international - 1 Jan 2014
de Mel Sanjay, Lim Su Hong, Tung Moon Ley, Chng Wee-Joo
Abstract excerpt
Multiple myeloma is the second most common hematologic malignancy in the world. Despite improvement in outcome, the disease is still incurable for most patients. However, not all myeloma are the same. With the same treatment, some patients can have very long survival whereas others can have very short survival. This suggests that there is underlying heterogeneity in myeloma. Studies over the years have revealed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.